ATE334694T1 - Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln - Google Patents
Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmittelnInfo
- Publication number
- ATE334694T1 ATE334694T1 AT02800641T AT02800641T ATE334694T1 AT E334694 T1 ATE334694 T1 AT E334694T1 AT 02800641 T AT02800641 T AT 02800641T AT 02800641 T AT02800641 T AT 02800641T AT E334694 T1 ATE334694 T1 AT E334694T1
- Authority
- AT
- Austria
- Prior art keywords
- thymulin
- peptides
- producing pain
- pain relieves
- relieves
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical class NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 abstract 1
- 108010087765 Antipain Proteins 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0112984A FR2830451B1 (fr) | 2001-10-09 | 2001-10-09 | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE334694T1 true ATE334694T1 (de) | 2006-08-15 |
Family
ID=8868083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02800641T ATE334694T1 (de) | 2001-10-09 | 2002-10-08 | Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7309690B2 (de) |
| EP (1) | EP1450843B1 (de) |
| JP (1) | JP4277684B2 (de) |
| AT (1) | ATE334694T1 (de) |
| AU (1) | AU2002362710B2 (de) |
| CA (1) | CA2463549C (de) |
| DE (1) | DE60213648T2 (de) |
| ES (1) | ES2272811T3 (de) |
| FR (1) | FR2830451B1 (de) |
| IL (2) | IL161319A0 (de) |
| WO (1) | WO2003030927A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| BR122018074353B8 (pt) | 2003-01-28 | 2023-05-02 | Ironwood Pharmaceuticals Inc | composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos |
| CN102772783A (zh) * | 2007-01-25 | 2012-11-14 | 中国生化制药工业协会 | 血清胸腺因子在制备抗肿瘤药物、肿瘤物理及化学治疗药物的保护药物方面的用途 |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| FR2930156B1 (fr) * | 2008-04-21 | 2011-10-28 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes. |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JP5964589B2 (ja) | 2008-12-03 | 2016-08-03 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法 |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
| FR2962335B1 (fr) | 2010-07-12 | 2013-01-18 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives |
| US9468662B2 (en) | 2010-07-12 | 2016-10-18 | Orphit | Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MX357121B (es) | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Proceso de preparacion de agonistas c de guanilato ciclasa. |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| RU2015107019A (ru) | 2012-08-21 | 2016-10-10 | Эрделикс Инк. | Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Zusammensetzungen zur behandlung von magen-darm-störungen |
| CN105392483B (zh) | 2013-04-12 | 2019-03-15 | 阿德利克斯公司 | 用于抑制磷酸盐转运的nhe3结合化合物和方法 |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| WO2017210726A1 (en) * | 2016-06-06 | 2017-12-14 | Clinical Stem Cells Pty Ltd | Peptides for hair growth |
| EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
| KR20240090875A (ko) | 2017-01-09 | 2024-06-21 | 알데릭스, 인코포레이티드 | 위장관 장애를 치료하는 데 유용한 화합물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4301065A (en) * | 1977-05-25 | 1981-11-17 | Agence Nationale De Valorisation De La Recherche (Anvar) | Novel polypeptides having thymic activity or an antagonistic activity and processes for their synthesis |
| DK221681A (da) | 1980-05-22 | 1981-11-23 | Inst Nat Sante | Fremgangsmaade til fremstilling af biologisk virksomme og radioimmunologisk anvendelige produkter ud fra serum-thymusfaktoren |
| JPS5852225A (ja) * | 1981-09-22 | 1983-03-28 | Mitsui Pharmaceut Inc | 脱髄疾患治療剤 |
| US5288706A (en) * | 1987-12-25 | 1994-02-22 | Mitsui Toatsu Chemicals, Incorporated | Medicament for prevention and remedy of diseases of the pancreas and others |
| JPH06192120A (ja) * | 1992-12-24 | 1994-07-12 | Mitsui Toatsu Chem Inc | 腎臓の組織・細胞の損傷・破壊の予防・治療剤 |
| JP3751986B2 (ja) * | 1994-06-21 | 2006-03-08 | 英良 横沢 | 医薬組成物 |
| US5639726A (en) * | 1994-09-30 | 1997-06-17 | The Regents Of The University Of Michigan | Peptide mediated enhancement of thrombolysis methods and compositions |
| US5808009A (en) * | 1996-09-23 | 1998-09-15 | North Dakota State University Research Foundation | Method of affinity purifying antibodies |
-
2001
- 2001-10-09 FR FR0112984A patent/FR2830451B1/fr not_active Expired - Fee Related
-
2002
- 2002-10-08 ES ES02800641T patent/ES2272811T3/es not_active Expired - Lifetime
- 2002-10-08 WO PCT/FR2002/003428 patent/WO2003030927A2/fr not_active Ceased
- 2002-10-08 JP JP2003533958A patent/JP4277684B2/ja not_active Expired - Fee Related
- 2002-10-08 CA CA2463549A patent/CA2463549C/fr not_active Expired - Fee Related
- 2002-10-08 AU AU2002362710A patent/AU2002362710B2/en not_active Ceased
- 2002-10-08 AT AT02800641T patent/ATE334694T1/de not_active IP Right Cessation
- 2002-10-08 DE DE60213648T patent/DE60213648T2/de not_active Expired - Lifetime
- 2002-10-08 EP EP02800641A patent/EP1450843B1/de not_active Expired - Lifetime
- 2002-10-08 US US10/492,170 patent/US7309690B2/en not_active Expired - Lifetime
- 2002-10-08 IL IL16131902A patent/IL161319A0/xx active IP Right Grant
-
2004
- 2004-04-07 IL IL161319A patent/IL161319A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2463549A1 (fr) | 2003-04-17 |
| WO2003030927A2 (fr) | 2003-04-17 |
| FR2830451A1 (fr) | 2003-04-11 |
| JP2005515972A (ja) | 2005-06-02 |
| CA2463549C (fr) | 2011-12-20 |
| AU2002362710B2 (en) | 2007-06-28 |
| AU2002362710B8 (en) | 2003-04-22 |
| EP1450843A2 (de) | 2004-09-01 |
| DE60213648T2 (de) | 2007-08-02 |
| FR2830451B1 (fr) | 2004-04-30 |
| ES2272811T3 (es) | 2007-05-01 |
| US7309690B2 (en) | 2007-12-18 |
| US20050261194A1 (en) | 2005-11-24 |
| JP4277684B2 (ja) | 2009-06-10 |
| WO2003030927A3 (fr) | 2003-10-09 |
| DE60213648D1 (de) | 2006-09-14 |
| EP1450843B1 (de) | 2006-08-02 |
| IL161319A0 (en) | 2004-09-27 |
| IL161319A (en) | 2008-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60213648D1 (de) | Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln | |
| DE60225118D1 (de) | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden | |
| IL161591A0 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
| TW200602071A (en) | Methods for preventing and treating alzheimer's disease (ad) | |
| ATE429922T1 (de) | Topische gel-abgabesysteme zur behandlung von hauterkrankungen | |
| DE69738581D1 (de) | Menschliche dnase i hyperaktive varianten | |
| ATE232393T1 (de) | Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung | |
| NL300830I1 (nl) | Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten | |
| GB2367061A (en) | Peptides | |
| YU68702A (sh) | Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka | |
| HUP9900789A2 (hu) | Lefelé irányuló szabályozásra rezisztens C3 konvertáz | |
| ATE356145T1 (de) | Polypeptide zur regenerierung des nervensystems | |
| DE59410423D1 (de) | Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose | |
| DE69738600D1 (de) | Neuroaktive peptide | |
| FI20050753A0 (fi) | Uudet peptidit | |
| ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| NO20004393L (no) | Anvendelse av CD137 for Õ fremme proliferering av perifere monocytter | |
| DE59805246D1 (de) | Tissue-faktor zur beeinflussung von gefässbildung | |
| ATE218866T1 (de) | Kombinationstherapie zur behandlung von aids | |
| DE69813620D1 (de) | Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten | |
| DE602006017806D1 (de) | Behandlung von neurodegeneration | |
| SE9703287D0 (sv) | Peptides | |
| ATE446766T1 (de) | Verwendung von alpha-s2 casein vorläufer- abgeleiteten peptiden | |
| ATE374021T1 (de) | Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post- chirurgischen schmerzbehandlung | |
| ATE226443T1 (de) | Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |